

Patient Information	Specimen Information	Client Information

Cardio IQ®

Test Name	Current		Risk/Reference Interval			Units	Historical Result & Risk
	Result & Risk		Optimal	Moderate	High		
	Optimal	Non-Optimal					
INFLAMMATION							
ADMA (Asymmetric dimethylarginine)	83		<100	100-123	>123	ng/mL	-
SDMA (Symmetric dimethylarginine)	96			73-135		ng/mL	-

For details on reference ranges please refer to the reference range/comment section of the report.

SPECIMEN:

Patient Information	Specimen Information	Client Information

Reference Range/Comments

Analyte Name	In Range	Out Range	Reference Range	Lab
ADMA	83		<100 ng/mL	
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Cardiometabolic Center of Excellence at Cleveland HeartLab. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Elevated ADMA levels are associated with significant subclinical atherosclerosis while elevated SDMA levels are associated with kidney function and strongly correlate with reduced eGFR. Available prospective studies suggest an increased risk of cardiovascular disease with higher ADMA concentrations (1). Based on an internal reference range study using 180 'apparently healthy,' non-smoking donors, CHL has defined the following cut-offs for ADMA: A cut-off of <100 ng/mL defines an 'apparently healthy' population at optimal relative risk for a cardiovascular event, 100-123 ng/mL defines a population at moderate relative risk for a cardiovascular event, and >123 ng/mL defines a high relative risk population. (Reference: 1-Willeit P. et al. J Am Heart Assoc. 2015; 4: e001833).				
SDMA	96		73-135 ng/mL	

SPECIMEN: